| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/04/2010 | US20100056459 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway |
| 03/04/2010 | US20100056456 Omega Conotoxins |
| 03/04/2010 | US20100056455 Therapies Which Act on Neuropeptide S Receptors |
| 03/04/2010 | US20100056444 Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| 03/04/2010 | US20100055696 DRG11-Responsive (DRAGON) Gene Family |
| 03/04/2010 | US20100055182 Use of guanidinoacetic acid (salts) combination with betaine and/or choline to produced an agent that is beneficial to health |
| 03/04/2010 | US20100055133 Pharmaceutical compositions |
| 03/04/2010 | US20100055109 Post-translationally modified neurotrophins |
| 03/04/2010 | US20100055075 Methods of treating ischemic spastiticy |
| 03/04/2010 | US20100055074 Light as a Replacement for Mitogenic Factors on Progenitor Cells |
| 03/04/2010 | US20100055073 Treatment of pervasive developmental disorders |
| 03/04/2010 | US20100055050 Nicotine chewing gum on a stick |
| 03/04/2010 | US20100055037 Treatment, prevention, and reversal of alcohol-induced brain disease |
| 03/04/2010 | CA2735768A1 Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/04/2010 | CA2735766A1 Novel piperidine-propionamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/04/2010 | CA2735497A1 New compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| 03/04/2010 | CA2735158A1 Compositions and methods of treating amyloid disease |
| 03/04/2010 | CA2734981A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 03/04/2010 | CA2730909A1 Method for treating multiple sclerosis patients with anti-il2r antibodies |
| 03/03/2010 | EP2159216A1 Ih - Modulators |
| 03/03/2010 | EP2158908A1 Composition for transdermal or transmucosal administration |
| 03/03/2010 | EP2158907A2 A composition for use as a medicament for topical application to skin |
| 03/03/2010 | EP2158903A2 Transparent Transdermal Nicotine Delivery Devices |
| 03/03/2010 | EP2158331A2 New polymorphisms in abcb1 associated with a lack of clinical response to medicaments |
| 03/03/2010 | EP2158318A2 Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| 03/03/2010 | EP2158209A2 Neurosteroid compounds |
| 03/03/2010 | EP2158202A1 New compounds 892 |
| 03/03/2010 | EP2158195A1 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders |
| 03/03/2010 | EP2158184A2 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators |
| 03/03/2010 | EP1937261B1 Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/03/2010 | EP1753719B1 Substituted pyrrolidine-2-ones |
| 03/03/2010 | EP1749001B1 3-piperidinylisochroman-5-ols as dopamine agonists |
| 03/03/2010 | EP1698622B1 Treatment for severe aphasia in chronic-stage cerebrovascular disorder |
| 03/03/2010 | EP1641456B1 Gaboxadol for treating depression and other affective disorders |
| 03/03/2010 | EP1542969B1 Pyrrolidone derivatives as maob inhibitors |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/03/2010 | EP1496920B1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation |
| 03/03/2010 | EP1424973B1 Disposal system for transdermal dosage form |
| 03/03/2010 | EP1389183B1 Sulfonamide derivatives |
| 03/03/2010 | EP1386908B1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 03/03/2010 | EP1100801B1 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 03/03/2010 | CN101659639A Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/03/2010 | CN101658486A Hydrous external preparation containing sodium loxoprofen |
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671177 Botulinum neurotoxin type E having increased biological half-life for use treatment and prevention of autonomic, neuromuscular and pain disorders |
| 03/02/2010 | US7671089 Levodopa prodrugs, and compositions and uses thereof |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671075 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide |
| 03/02/2010 | US7671074 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others; N-{amino-[pyridin-2-yl-methyl)-amino]-methylene}-4-methylbenzenesulfonamide |
| 03/02/2010 | US7671050 (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors |
| 03/02/2010 | US7671048 gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; cyclopropyl-[3-fluoro-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepin-10-yl]-methanone, |
| 03/02/2010 | US7671036 Positively-charged peptide nucleic acid analogs with improved properties |
| 03/02/2010 | US7670829 from a simple carbon source; includes 17 alpha -hydroxypregnenolone, cortisol, cortexolone, 17 alpha -hydroxyprogesterone, and derivatives; genetic engineering |
| 03/02/2010 | US7670791 regulating an alpha 1G T-type calcium channel in the central nervous system and alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system; analegesic |
| 03/02/2010 | US7670608 Selection of patients with increased responsiveness to botulinum toxin |
| 03/02/2010 | CA2519117C High potency dopaminergic treatment of neurological impairment associated with brain injury |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 02/25/2010 | WO2010022249A2 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | WO2010021797A1 Condensed heterocyclic compounds having 5-ht6 receptor affinity |
| 02/25/2010 | WO2010021766A1 Hydroxybutyrate ester and medical use thereof |
| 02/25/2010 | WO2010021715A1 Treatment of stroke using isolated placental cells |
| 02/25/2010 | WO2010021697A2 Antibodies to ccr2 |
| 02/25/2010 | WO2010021412A1 Therapeutic material for cerebral infarction, and method for regeneration of brain tissue |
| 02/25/2010 | WO2010021247A1 Pharmaceutical preparation, food or beverage having inhibitory activity on serotonin transporter |
| 02/25/2010 | WO2010021129A1 Apoptosis inhibitor |
| 02/25/2010 | WO2010020970A1 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
| 02/25/2010 | WO2010020969A1 An extended release pharmaceutical composition of entacapone or salts thereof |
| 02/25/2010 | WO2010020920A2 Anti-parkinsonian compound acetylsalicylic acid maltol ester |
| 02/25/2010 | WO2010020762A1 1,5-diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists |
| 02/25/2010 | WO2010020672A1 Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors |
| 02/25/2010 | WO2010020651A1 Treatment of anxiety disorders |
| 02/25/2010 | WO2010020610A1 Compounds for the treatment of peripheral neuropathies |
| 02/25/2010 | WO2010020609A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 02/25/2010 | WO2010020585A1 Serotonin reuptake inhibitors for the treatment of rett syndrome |
| 02/25/2010 | WO2010020548A1 Glyt1 receptor antagonists |
| 02/25/2010 | WO2010020000A1 Novel compounds and their uses in diagnosis |
| 02/25/2010 | WO2010003046A3 Gabapentin enacarbil salts and processes for their preparation |
| 02/25/2010 | WO2010000763A3 Combinations comprising mglur modulators for the treatment of parkinson's disease |
| 02/25/2010 | WO2009158446A3 Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof |
| 02/25/2010 | WO2009152041A3 Controlled release formulations of pramipexole |
| 02/25/2010 | WO2009148659A3 Antimalarial quinolines and methods of use thereof |
| 02/25/2010 | WO2009146218A8 Compounds including an anti-inflammatory pharmacore and methods of use |
| 02/25/2010 | WO2009145816A3 Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| 02/25/2010 | WO2009140621A3 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| 02/25/2010 | WO2009137795A3 Methods for treating endoplasmic reticulum (er) stress disorders |
| 02/25/2010 | WO2009115651A3 N-phenyl-imidazo[1,2-a]pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106752A3 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106751A3 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2- a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009008694A8 Pharmaceutical composition comprising the combination of an anti-depressive agent and an ansiolytic agent for control and treatment of depressive disorders |
| 02/25/2010 | US20100048731 Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents |
| 02/25/2010 | US20100048727 Perfluoroketone compounds and uses thereof |
| 02/25/2010 | US20100048726 Memantine For The Treatment Of Mild And Mild To Moderate Alzheimer's Disease |
| 02/25/2010 | US20100048722 FORMATION OF ACCUMBENS GluR2-LACKING AMPA RECEPTORS MEDIATES INCUBATION OF COCAINE CRAVING |
| 02/25/2010 | US20100048721 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| 02/25/2010 | US20100048720 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
| 02/25/2010 | US20100048719 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
| 02/25/2010 | US20100048718 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
| 02/25/2010 | US20100048711 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/25/2010 | US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c |